
eNewsletter

Free CDCES Coach App
Free Med Pocket Cards

For last weekβs practice question, we quizzed participants on which assessment is most important. 79% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!
Before we start though, if you donβt want any spoilers and havenβt tried the question yet, you can answer it byΒ clicking here.
A diabetes healthcare professional (HCP) is reviewing the clinics registry of individuals with diabetes to help close quality gaps. The HCP identifies a person (JR) with type 2 diabetes using a continuous glucose monitor (CGM) that has received recent diabetes education. However, there is no documented A1c or Glucose Management Indicator (GMI) in the medical record for the current measurement year, and the individualβs CGM data is not being shared with the healthcare team.
What is the MOST appropriate next step?

If you are thinking about taking the certification exam, this practice test question will set you up for success. Test writers anticipate possible answers based on the details in the question. They will wave those βjuicy answersβ right under your nose. Your job is to weed through the particulars, pluck out the most important elements and choose the BEST answer.
Answer A is correct. 78.71% chose this answer: “Establish CGM data sharing with JR to obtain a qualifying GMI or obtain an A1c.” Great job! This is the correct answer.
The most appropriate next step is to proactively address the missing glycemic measurement by collaborating with JR to establish CGM data sharing and obtain a qualifying Glucose Management Indicator (GMI), or arrange for an A1C measurement. Although JR is already using CGM and has received diabetes education, neither activity alone satisfies the glycemic measurement requirement. By helping JR share CGM data, the healthcare professional can assess glucose patterns, identify opportunities to improve diabetes management, and potentially close the quality gap. This approach supports person-centered care, coordinated team-based management, and proactive population health strategies.
Answer B is incorrect. 3.23% of you chose this answer, “Document that JR uses CGM to close the quality gap and meet the necessary criteria.”Β
Simply documenting CGM use does not satisfy a quality measure requiring a documented glycemic result. The healthcare team must obtain and document an eligible A1C or GMI value according to the measure specifications. CGM use is valuable for diabetes management, but device use alone does not establish that the required measurement has been completed.
Answer C is incorrect. 16.77% of respondents chose this: “Encourage JR to continue using the CGM and reassess their Ambulatory Glucose Profile (AGP) at the next scheduled visit.”Β
Encouraging ongoing CGM use and reviewing the AGP are important components of diabetes care. However, postponing the review misses an opportunity to address the current quality gap. Since JR is already wearing a CGM, establishing data sharing now may provide the information needed to assess glucose management and document an eligible GMI without waiting for the next appointment.
Finally, Answer D is incorrect. 1.29% chose this answer, “Wait for the primary care provider to identify and address JRβs missing measure to close the quality gap.”
Closing quality gaps is a shared responsibility across the healthcare team. Diabetes care and education specialists can play an active role in reviewing registries, identifying missing measures, coordinating appropriate testing, and helping people share CGM data. Waiting for another clinician to act can delay needed follow-up and opportunities to improve care.
We hope you appreciate this weekβs rationale! Thank you so much for taking the time to answer our Test You Knowledge Tuesday and participate in this fun learning activity!
Get 30% Off Our Entire Collection of


For last weekβs practice question, we quizzed participants on what the next step for numbness and fatigue is. 66% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!
Before we start though, if you donβt want any spoilers and havenβt tried the question yet, you can answer it byΒ clicking here.
A 62-year-old adult with type 2 diabetes has been taking metformin 1,000 mg twice daily for the past 8 years. At a routine follow-up, they report new numbness and tingling in both feet and increased fatigue. Their point-of-care A1C is 7.1%, and a recent nutrition history suggests limited intake of animal-source foods.
What is the most appropriate next step for the diabetes care team?

If you are thinking about taking the certification exam, this practice test question will set you up for success. Test writers anticipate possible answers based on the details in the question. They will wave those βjuicy answersβ right under your nose. Your job is to weed through the particulars, pluck out the most important elements and choose the BEST answer.
Answer A is incorrect. 16.79% chose this answer: “Ensure the patient has completed a comprehensive foot examination and discuss the risk of diabetic peripheral neuropathy.”
An annual comprehensive foot examination is important and may identify loss of protective sensation; however, new numbness and tingling justify further evaluation. Keep reading to learn more.
Answer B is incorrect. 8.55% of you chose this answer, “Recommend increasing dietary protein and iron intake to treat potential nutritional anemia.”
Fatigue may be associated with anemia, and assessing overall dietary adequacy in the setting of low animal-based foods is appropriate. However, this may not address the new numbness and tingling in the feet and may miss other nutritional deficiencies.
Answer C is correct. 65.65% of respondents chose this: “Obtain a serum vitamin B12 level and evaluate for deficiency.” Great job! This is the correct answer.
Long-term metformin use, along with low animal-based food intake, puts this individual at risk for vitamin B12 deficiency. Vitamin B12 deficiency can cause fatigue, anemia, and neurologic symptoms that may resemble or contribute to diabetic peripheral neuropathy. In addition to other assessments, requesting a serum vitamin B12 and/or methylmalonic acid level is an appropriate next step.
Finally, Answer D is incorrect. 9.01% chose this answer, “Recommend adding another glucose-lowering medication because their A1C is above the ADA Standard of Care target.”
Although an A1C of 7.1% may exceed an individualized glycemic target, we should determine the need for additional glucose-lowering medication based on the patientβs treatment goals and overall clinical status, which we donβt have enough information to define. In addition, intensifying glycemic management would not address the immediate need to investigate new neurologic symptoms and fatigue.
We hope you appreciate this weekβs rationale! Thank you so much for taking the time to answer our Test You Knowledge Tuesday and participate in this fun learning activity!
Want to Learn More?
Explore the magnificent world of diabetes and the gut β from periodontal disease to the microbiome and everything in between.
The GI system plays a far bigger role in diabetes than most clinicians realize. Join Coach Beverly Thomassian, RN, MPH, CDCES, BC-ADM for a fascinating journey through gastrointestinal health from top to bottom. This course covers fatty liver disease, gastroparesis, intestinal complications of diabetes, the gut microbiome, and more β giving you the knowledge to better support whole-body health.

For last weekβs practice question, we quizzed participants on which assessment is most important. 43% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!
Before we start though, if you donβt want any spoilers and havenβt tried the question yet, you can answer it byΒ clicking here.
CJ is a 13-year-old teenager with type 1 diabetes diagnosed less than a week ago. You are seeing CJ and their parents for the first DSME visit.
Based on CJβs recent diagnosis, which of the following would be most important to assess?

If you are thinking about taking the certification exam, this practice test question will set you up for success. Test writers anticipate possible answers based on the details in the question. They will wave those βjuicy answersβ right under your nose. Your job is to weed through the particulars, pluck out the most important elements and choose the BEST answer.
Answer A is incorrect. 21.28% chose this answer: “Since CJ is newly diagnosed and still in the honeymoon phase, they will need low doses of insulin.”
The honeymoon phase, or partial clinical remission, occurs when remaining pancreatic beta cells temporarily produce enough insulin to reduce exogenous insulin requirements. However, not everyone experiences this phase, and its onset, duration, and degree of insulin production vary. Since CJ was diagnosed less than a week ago, it would be premature to assume they are experiencing the honeymoon phase. Insulin dosing should be individualized based on glucose patterns, carbohydrate intake, insulin sensitivity, and clinical assessment.
Answer B is correct. 42.66% of you chose this answer, “Has anyone mentioned teplizumab (Tzield) therapy as an option to slow beta cell destruction?” Great job! This is the correct answer.
Teplizumab (Tzield) is a CD3-directed monoclonal antibody that received FDA accelerated approval in June 2026 to delay the decline in endogenous insulin production in children and adolescents ages 8β17 with recently diagnosed stage 3 type 1 diabetes. Treatment must be initiated within 8 weeks of diagnosis. Since CJ is 13 years old and was diagnosed less than a week ago, discussing teplizumab and referring CJ for an eligibility evaluation would be appropriate. Eligibility requires at least one positive pancreatic islet autoantibody and evidence of residual insulin production, including a stimulated peak C-peptide of at least 0.2 pmol/mL. The PROTECT trial demonstrated that teplizumab significantly slowed the decline in beta cell function compared with placebo over 78 weeks. Although teplizumab does not eliminate the need for insulin therapy, it represents an important disease-modifying treatment option for eligible youth with newly diagnosed type 1 diabetes.
Answer C is incorrect. 10.06% of respondents chose this: “Do you know to be aware of any signs of gluten intolerance or thyroid issues?”Β
Children and adolescents with type 1 diabetes have an increased risk of developing autoimmune thyroid disease and celiac disease. Screening for these conditions is an important component of comprehensive diabetes care. However, given CJ’s very recent diagnosis, discussing the potential benefits of teplizumab is a more time-sensitive priority because treatment must begin within 8 weeks of diagnosis. Screening and education about associated autoimmune conditions should still be included in CJ’s ongoing diabetes management.
Finally, Answer D is incorrect. 26% chose this answer, “Did you know that most teenagers experience significant diabetes distress during the first year of diagnosis?”
Adolescents with type 1 diabetes are at increased risk for diabetes distress and other psychosocial challenges, especially as they adjust to a new diagnosis. However, stating that most teenagers experience significant distress during the first year is an overgeneralization that may unnecessarily alarm CJ and their parents. A more appropriate approach would be to ask open-ended questions about how CJ and their family are coping, normalize a range of emotional responses, and offer psychosocial support as needed.
We hope you appreciate this weekβs rationale! Thank you so much for taking the time to answer our Test You Knowledge Tuesday and participate in this fun learning activity!

Thinking about becoming a Certified Diabetes Care and Education Specialist (CDCES)?
This FREE, information-packed webinar will walk you through the exact steps required to earn your CDCES credential β and help you create an effective study plan to make it over the finish line!

For last weekβs practice question, we quizzed participants on what the next step should be for too much weight loss. 87% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!
Before we start though, if you donβt want any spoilers and havenβt tried the question yet, you can answer it byΒ clicking here.
JR is a 68-year-old with type 2 diabetes who started semaglutide (Ozempic) 5 months ago and now takes 2.0mg weekly. Their A1C has decreased from 8.2% to 6.4%, and they have lost 24 pounds (11% of their initial body weight). JR is pleased with their improved glucose levels but concerned about their declining strength and lack of appetite.
Which of the following is the most appropriate next step for the diabetes care and education specialist?

If you are thinking about taking the certification exam, this practice test question will set you up for success. Test writers anticipate possible answers based on the details in the question. They will wave those βjuicy answersβ right under your nose. Your job is to weed through the particulars, pluck out the most important elements and choose the BEST answer.
Answer A is incorrect. 8.85% chose this answer: “Explain that muscle loss is expected with GLP-1 therapy and encourage JR to continue their current eating pattern with a focus on protein intake.”
Although some lean body mass loss may accompany weight reduction, clinically meaningful muscle weakness and functional decline is not acceptable or inevitable consequences of GLP-1 therapy. JR’s symptoms warrant prompt assessment and intervention to prevent further loss of strength, mobility, and independence.
Answer B is incorrect. 1.77% of you chose this answer, “Recommend increasing fluid and carbohydrate intake to prevent further weight loss while maintaining the current semaglutide dose.”Β
Increasing carbohydrate intake alone does not adequately address JR’s nutritional deficiencies or declining muscle function. The focus should be on sufficient total energy, high-quality protein, and nutrient-dense foods. The current medication regimen should also be reassessed in light of JR’s reduced appetite and functional decline.
Answer C is incorrect. 2.21% of respondents chose this: “Suggest discontinuing semaglutide immediately and initiating basal insulin to prevent further muscle loss.”Β
Automatically discontinuing GLP-1 therapy and replacing it with insulin is not an evidence-based strategy for treating sarcopenia. JR’s glucose management has improved, and semaglutide may continue to provide important cardiometabolic benefits. The healthcare team should assess the severity of nutritional compromise, consider dose adjustment or discontinuation when clinically indicated, and implement interventions to improve muscle health. Insulin does not directly treat sarcopenia.
Finally, Answer D is correct. 87.17% chose this answer, “Collaborate with JR and provider to reassess GLP-1 therapy and refer JR to an RDN for MNT.” Great job, this is the best answer!
Although GLP-1 receptor agonists can provide substantial glycemic and cardiometabolic benefits, reduced appetite and early satiety may contribute to inadequate energy and protein intake. Rapid or substantial weight loss can include loss of lean body mass, particularly in older adults. The priority is to preserve muscle strength and function while maintaining the benefits of diabetes treatment. A comprehensive approach includes assessing nutritional adequacy, referring to an RDN for individualized energy and protein recommendations, incorporating progressive resistance training as tolerated, and collaborating with the prescribing provider to evaluate whether the current GLP-1 dose remains appropriate.
We hope you appreciate this weekβs rationale! Thank you so much for taking the time to answer our Test You Knowledge Tuesday and participate in this fun learning activity!

The U.S. healthcare system is rapidly shifting toward digital quality reporting, transforming how diabetes outcomes are measured, reimbursed, and improved.
In this 1-hour and 15-minute program. Dr. Marie Frazzitta, DNP, FNPβC, PMHNP, CDCES, MBA, explores how national quality initiatives are modernizing diabetes metrics, including the integration of CGM-derived indicators and the upcoming measure that will track CGM adoption. Weβll also highlight the operational realities of digital reporting and show how DCESs can leverage these trends to expand their impact, strengthen care equity, and become strategic partners in quality improvement and population health.

For last weekβs practice question, we quizzed participants on how many pens are needed per month. 48% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!
Before we start though, if you donβt want any spoilers and havenβt tried the question yet, you can answer it byΒ clicking here.
JR needs to inject 70 units of degludec (Tresiba) a day and says he keeps running out of this basal insulin. The diabetes healthcare professional suggests changing the insulin concentration from U-100 to U-200, so his supplies last longer.
How many degludec U-200 insulin pens would JR need a month based on his current insulin dose? (You can check out our Insulin Dosing and Storage Sheet for more info)

If you are thinking about taking the certification exam, this practice test question will set you up for success. Test writers anticipate possible answers based on the details in the question. They will wave those βjuicy answersβ right under your nose. Your job is to weed through the particulars, pluck out the most important elements and choose the BEST answer.
Answer A is incorrect. 13.58% chose this answer: “7 Pens.”
Seven pens would be approximately the number needed if the pens contained only 300 units each. Tresiba U-200 contains 600 units per 3-mL pen, so fewer pens are required than with a U-100 formulation.
Answer B is correct. 47.80% of you chose this answer, “4 Pens.” Great job! This is the correct answer.
JR requires approximately 2,100 units per month. Each U-200 pen contains 600 units, so 2,100 Γ· 600 = 3.5 pens. Since a partial pen cannot meet the full monthly requirement, JR would need 4 pens. Calculation: JR uses 70 units/day Γ 30 days = 2,100 units/month. Each Tresiba U-200 pen contains 600 units (3 mL Γ 200 units/mL). Therefore, 2,100 Γ· 600 = 3.5 pens, which must be rounded up to 4 pens per month.
Answer C is incorrect. 28.04% of respondents chose this: “3.5 Pens”Β
Mathematically, JR will use the equivalent of 3.5 pens during a 30-day period. However, pens are dispensed as whole pens, not partial pens. Therefore, the quantity must be rounded up to 4 pens to ensure JR has enough insulin for the entire month. Three U-200 pens provide only 1,800 units (600 Γ 3) and since we canβt add in a half a pen, this approach wouldnβt work.
Finally, Answer D is incorrect. 10.58% chose this answer, “5 Pens”
Five pens would provide 3,000 units (600 units x 5) substantially more than JR’s calculated 30-day requirement of 2,100 units. Four pens provide 2,400 units and are sufficient for the month.
Clinical Pearl: The advantage of U-200 degludec is that the same insulin dose is delivered in a smaller volume, and each pen contains more total units. Please use our Insulin Dosing and Storage Sheet as a helpful resource for insulin calculations and the latest information. Our FREE Cheat sheets are also available on our CDCES Coach App for Easy Reference.
We hope you appreciate this weekβs rationale! Thank you so much for taking the time to answer our Test You Knowledge Tuesday and participate in this fun learning activity!
πUpdated Schedule: ADA Boot Camp, Tech, MNT & More
Live in Beautiful San Diego – Oct 22-23, 2026
Re-Ignite your Passion & Prepare for Diabetes Certification Exams
π Earn 30+ CEs: AMA PRA Category 1 Creditsβ’, ACPE, ANCC, and CDR!
π
2-Day Conference
Oct 22β23, 2026
β±οΈ
15.5 Live CEs
+ 17 bonus CEs
π
CDCES & BC-ADM
Exam Prep + Renewal
π
San Diego, CA
1.7 mi from airport
The field of diabetes care is expanding and evolving rapidly. This unique training conference will keep you on the cutting edge plus prepare you for certification exams. It also fulfills the Standards of Care renewal requirement. Join us for two days of intensive education that is fun and inspiring. Add on the optional Day 3 (Engaging the Disengaged), to complete your conference exeperience.
Coach Beverly and Diana Isaacs, PharmD, BC-ADM, CDCES co-lead an exciting day that brings the ADA and AACE Standards to life. Gain fresh insights, practical tools, and a deeper understanding of the latest in person-centered diabetes care. After attending, you will be empowered to share the latest in diabetes care with your colleagues and the people in your care.
Take your knowledge to the next level with this intensive deep-dive into insulin therapy, dosing and pattern management with Dr. Diana Isaacs. Next, stay for the diabetes tech show-and-tell as Diana demonstrates the specs of the latest pumps and sensors. After lunch, nutrition whiz Christine Craig, MS, RDN, CDCES expertly details the latest in MNT and provides real strategies on translating this content to your clinical practice. You will have a chance to put it all together as Coach Beverly leads you through a series of case studies that integrates content from Day 1 and Day 2.
On Saturday, join this exceptional day-long program led by William H. Polonsky, PhD, CDCES & Susan Guzman, PhD (Behavioral Diabetes Institute) that reveals psychosocial forces behind diabetes self-management β tools to break through resistance and inspire change.
Read more below
π Essentials
Registration
+ Printed Syllabus
$559.00
π Deluxe
Essentials
+ ADA Standards Book
$589.00
π Complete – Best Value!
Deluxe
+ ADCES Review Guide e-Book
$669.00

Transform how you engage patients with diabetes β master behavior change, reduce distress, and overcome medication hesitancy.
Why do so many patients know what they should do β but still struggle to do it?
The answer lies in the psychology of diabetes.
In this transformative full-day course, world-renowned experts William H. Polonsky, PhD, CDCES, and Susan Guzman, PhD, from the Behavioral Diabetes Institute reveal the hidden psychosocial forces that drive β or derail β diabetes self-management.
Youβll walk away with a completely new toolkit for breaking through patient resistance, dissolving medication hesitancy, and creating clinical encounters that actually inspire change!

For last weekβs practice question, we quizzed participants on the latest nutritional guidelines. 66% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!
Before we start though, if you donβt want any spoilers and havenβt tried the question yet, you can answer it byΒ clicking here.
Which of the following best reflects the ADAβs current nutrition guidance for people with diabetes?

If you are thinking about taking the certification exam, this practice test question will set you up for success. Test writers anticipate possible answers based on the details in the question. They will wave those βjuicy answersβ right under your nose. Your job is to weed through the particulars, pluck out the most important elements and choose the BEST answer.
Answer A is incorrect. 19.28% chose this answer: “Choose a Mediterranean or low-carbohydrate diet, because these approaches are superior for diabetes management.”
The ADA does not recommend one specific eating pattern for everyone with diabetes. Mediterranean, DASH, low-carbohydrate, vegetarian, vegan, and other eating patterns can be appropriate when individualized to the personβs preferences, needs, and goals.
Answer B is incorrect. 3.14% of you chose this answer, “Focus primarily on carbohydrate quantity and recommend limiting fruit, legumes, and whole grains because they contain carbohydrate.”
Carbohydrate quality matters, not simply the amount of carbohydrate. The ADA encourages minimally processed, nutrient-dense, high-fiber carbohydrate sources. Fruit and whole grains do not need to be routinely eliminated simply because they contain carbohydrate.
Answer C is incorrect. 66.37% of respondents chose this: “Emphasize nonstarchy vegetables, whole fruits, legumes, whole grains, nuts and seeds, lean proteins, and low-fat dairy or nondairy alternatives while minimizing red meat, sugar-sweetened beverages, sweets, refined grains, and processed and ultra-processed foods.”Β
Great job! This is the correct answer. The 2026 ADA Standards of Care recommend eating patterns that emphasize key nutrition principles, including consumption of non-starchy vegetables, whole fruits, legumes, lean proteins, whole grains, nuts and seeds, and low-fat dairy or nondairy alternatives, while minimizing red meat, sugar-sweetened beverages, sweets, refined grains, and processed and ultraprocessed foods.
Finally, Answer D is incorrect. 30% chose this answer, “Focus on a carbohydrate-controlled meal plan, primarily eliminating added sugar and saturated fat.”
The ADA encourages a food-based approach that considers the overall eating pattern rather than focusing solely on individual nutrients. Added sugars and saturated fat are important considerations, but guidance goes beyond individual nutrients. It emphasizes the overall quality of the eating pattern, including increasing nutrient-dense foods while minimizing refined grains, sugar-sweetened beverages, and ultra-processed foods.
We hope you appreciate this weekβs rationale! Thank you so much for taking the time to answer our Test You Knowledge Tuesday and participate in this fun learning activity!
πUpdated Schedule: ADA Boot Camp, Tech, MNT & More
Live in Beautiful San Diego – Oct 22-23, 2026
Re-Ignite your Passion & Prepare for Diabetes Certification Exams
π Earn 30+ CEs: AMA PRA Category 1 Creditsβ’, ACPE, ANCC, and CDR!
π
2-Day Conference
Oct 22β23, 2026
β±οΈ
15.5 Live CEs
+ 17 bonus CEs
π
CDCES & BC-ADM
Exam Prep + Renewal
π
San Diego, CA
1.7 mi from airport
The field of diabetes care is expanding and evolving rapidly. This unique training conference will keep you on the cutting edge plus prepare you for certification exams. It also fulfills the Standards of Care renewal requirement. Join us for two days of intensive education that is fun and inspiring. Add on the optional Day 3 (Engaging the Disengaged), to complete your conference exeperience.
Coach Beverly and Diana Isaacs, PharmD, BC-ADM, CDCES co-lead an exciting day that brings the ADA and AACE Standards to life. Gain fresh insights, practical tools, and a deeper understanding of the latest in person-centered diabetes care. After attending, you will be empowered to share the latest in diabetes care with your colleagues and the people in your care.
Take your knowledge to the next level with this intensive deep-dive into insulin therapy, dosing and pattern management with Dr. Diana Isaacs. Next, stay for the diabetes tech show-and-tell as Diana demonstrates the specs of the latest pumps and sensors. After lunch, nutrition whiz Christine Craig, MS, RDN, CDCES expertly details the latest in MNT and provides real strategies on translating this content to your clinical practice. You will have a chance to put it all together as Coach Beverly leads you through a series of case studies that integrates content from Day 1 and Day 2.
On Saturday, join this exceptional day-long program led by William H. Polonsky, PhD, CDCES & Susan Guzman, PhD (Behavioral Diabetes Institute) that reveals psychosocial forces behind diabetes self-management β tools to break through resistance and inspire change.
Read more below
π Essentials
Registration
+ Printed Syllabus
$559.00
π Deluxe
Essentials
+ ADA Standards Book
$589.00
π Complete – Best Value!
Deluxe
+ ADCES Review Guide e-Book
$669.00

Transform how you engage patients with diabetes β master behavior change, reduce distress, and overcome medication hesitancy.
Why do so many patients know what they should do β but still struggle to do it?
The answer lies in the psychology of diabetes.
In this transformative full-day course, world-renowned experts William H. Polonsky, PhD, CDCES, and Susan Guzman, PhD, from the Behavioral Diabetes Institute reveal the hidden psychosocial forces that drive β or derail β diabetes self-management.
Youβll walk away with a completely new toolkit for breaking through patient resistance, dissolving medication hesitancy, and creating clinical encounters that actually inspire change!

For last weekβs practice question, we quizzed participants on if AACE recommends medications to treat prediabetes. 90% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!
Before we start though, if you donβt want any spoilers and havenβt tried the question yet, you can answer it byΒ clicking here.
A 36-year-old has an A1C of 6.2%, BMI of 36, hypertension, and a strong family history of type 2 diabetes. Despite sustained nutrition and physical activity interventions, they canβt seem to lower their A1C. They ask whether medication could help reduce their risk of developing type 2 diabetes.
Which approach is MOST consistent with American Association of Clinical Endocrinology (AACE) recommendations?

If you are thinking about taking the certification exam, this practice test question will set you up for success. Test writers anticipate possible answers based on the details in the question. They will wave those βjuicy answersβ right under your nose. Your job is to weed through the particulars, pluck out the most important elements and choose the BEST answer.
Answer A is incorrect. 5.10% chose this answer: “Avoid pharmacologic treatment until the A1C or FPG reaches the diagnostic threshold for diabetes.”Β
This may have been true in the past, but both the ADA and AACE now recommend considering pharmacologic treatment in the prediabetes phase to delay or prevent a future diabetes diagnosis.
Answer B is correct. 89.80% of you chose this answer, “Consider pharmacotherapy, including metformin or GLP-1βbased therapy to reduce metabolic risk.” Great job! This is the correct answer.Β
Prediabetes provides an opportunity for active intervention rather than watchful waiting. AACE recommends addressing excess adiposity and associated metabolic complications as part of diabetes prevention. For an individual with obesity and prediabetes, evidence-based obesity pharmacotherapy may be considered alongside nutrition, physical activity, behavioral support, and management of cardiovascular risk factors. Current AACE guidance takes a patient-centered, complication-focused approach to obesity/adiposity-based chronic disease rather than relying on BMI or glucose alone.
Answer C is incorrect. 3.06% of respondents chose this: “Initiate a sulfonylurea to improve beta-cell function and prevent progression to type 2 diabetes.”Β
Is not the best answer since sulfonylureas arenβt recommended as diabetes-prevention therapy and carry risks including hypoglycemia and weight gain.
Finally, Answer D is incorrect. 2.04% chose this answer, “Initiate basal insulin to preserve pancreatic beta-cell function and lower A1C.”
Not the best answer since insulin is not routinely used to delay progression from prediabetes to type 2 diabetes.
We hope you appreciate this weekβs rationale! Thank you so much for taking the time to answer our Test You Knowledge Tuesday and participate in this fun learning activity!
πUpdated Schedule: ADA Boot Camp, Tech, MNT & More
Live in Beautiful San Diego – Oct 22-23, 2026
Re-Ignite your Passion & Prepare for Diabetes Certification Exams
π Earn 30+ CEs: AMA PRA Category 1 Creditsβ’, ACPE, ANCC, and CDR!
π
2-Day Conference
Oct 22β23, 2026
β±οΈ
15.5 Live CEs
+ 17 bonus CEs
π
CDCES & BC-ADM
Exam Prep + Renewal
π
San Diego, CA
1.7 mi from airport
The field of diabetes care is expanding and evolving rapidly. This unique training conference will keep you on the cutting edge plus prepare you for certification exams. It also fulfills the Standards of Care renewal requirement. Join us for two days of intensive education that is fun and inspiring. Add on the optional Day 3 (Engaging the Disengaged), to complete your conference exeperience.
Coach Beverly and Diana Isaacs, PharmD, BC-ADM, CDCES co-lead an exciting day that brings the ADA and AACE Standards to life. Gain fresh insights, practical tools, and a deeper understanding of the latest in person-centered diabetes care. After attending, you will be empowered to share the latest in diabetes care with your colleagues and the people in your care.
Take your knowledge to the next level with this intensive deep-dive into insulin therapy, dosing and pattern management with Dr. Diana Isaacs. Next, stay for the diabetes tech show-and-tell as Diana demonstrates the specs of the latest pumps and sensors. After lunch, nutrition whiz Christine Craig, MS, RDN, CDCES expertly details the latest in MNT and provides real strategies on translating this content to your clinical practice. You will have a chance to put it all together as Coach Beverly leads you through a series of case studies that integrates content from Day 1 and Day 2.
On Saturday, join this exceptional day-long program led by William H. Polonsky, PhD, CDCES & Susan Guzman, PhD (Behavioral Diabetes Institute) that reveals psychosocial forces behind diabetes self-management β tools to break through resistance and inspire change.
Read more below
π Essentials
Registration
+ Printed Syllabus
$559.00
π Deluxe
Essentials
+ ADA Standards Book
$589.00
π Complete – Best Value!
Deluxe
+ ADCES Review Guide e-Book
$669.00

Transform how you engage patients with diabetes β master behavior change, reduce distress, and overcome medication hesitancy.
Why do so many patients know what they should do β but still struggle to do it?
The answer lies in the psychology of diabetes.
In this transformative full-day course, world-renowned experts William H. Polonsky, PhD, CDCES, and Susan Guzman, PhD, from the Behavioral Diabetes Institute reveal the hidden psychosocial forces that drive β or derail β diabetes self-management.
Youβll walk away with a completely new toolkit for breaking through patient resistance, dissolving medication hesitancy, and creating clinical encounters that actually inspire change!

For last weekβs practice question, we quizzed participants on which response BEST supports sustainable medication-taking. 68% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!
Before we start though, if you donβt want any spoilers and havenβt tried the question yet, you can answer it byΒ clicking here.
CJ is living with type 1 diabetes and calls the diabetes-education clinic, recently learning she is 7-weeks gestation. CJ uses a hybrid closed-loop (automated insulin delivery or AID) insulin pump system with continuous glucose monitoring that is set to a target to 110 mg/dl. The Ambulatory Glucose Profile report was reviewed for the past 2 weeks and findings show increasing postprandial hyperglycemia, with average post-meal readings of 170β220 mg/dL. Time in Range (TIR) is 72% (70-180 mg/dl) with 1% of Time below Range. The total daily insulin dose has increased approximately 10% over the same period. And CJ reports no significant changes to diet, activity, or carbohydrate intake. CJ asks if any modifications are need to the diabetes therapy plan?
What can we tell CJ?

If you are thinking about taking the certification exam, this practice test question will set you up for success. Test writers anticipate possible answers based on the details in the question. They will wave those βjuicy answersβ right under your nose. Your job is to weed through the particulars, pluck out the most important elements and choose the BEST answer.
Answer A is incorrect. 9.65% chose this answer: “Reassure her that increasing insulin resistance is expected as pregnancy progresses and suggest an increase in her basal insulin by 10-20%.”
Although we will anticipate an increase in insulin needs as pregnancy progresses, we do not yet have enough information to increase the basal rate. The pattern identified above was post-prandial hyperglycemia, making a recommendation for basal increase without additional information inappropriate.
Answer B is incorrect. 5.26% of you chose this answer, βDiscontinue the AID system and transition her to manual mode pump therapy since, since AID systems are not intended for use in pregnancy.β
Pregnancy is not, by itself, a reason to discontinue AID. The use of AID during pregnancy is an evolving area, and the appropriateness of continued use depends on the specific system and its regulatory status, capabilities, and glucose targets. In April 2026, the FDA cleared Tandem’s Control-IQ+ technology1 for use during pregnancy in people with type 1 diabetes. Other AID systems may have different indications or may be used off-label. Additional assessment is recommended before AID discontinuation.
Answer C is incorrect. 16.67% of respondents chose this: “Time is Range is over 70%, meeting the ADA Standard of Care targets, however, due to post-prandial hyperglycemia recommend a lower (more aggressive) insulin-to-carbohydrate ratio.”
A lower (more aggressive) insulin-to-carbohydrate ratio may ultimately be appropriate for persistent postprandial hyperglycemia, but the initial TIR reported uses the standard 70β180 mg/dL range and does not adequately assess pregnancy-specific glycemic targets. For pregnant individuals with type 1 diabetes, the recommended CGM target range is 63β140 mg/dL, with a goal of spending >70% of time in this range. Additional goals include <4% time below 63 mg/dL, <1% below 54 mg/dL, and <25% above 140 mg/dL.2
Finally, Answer D is correct. 68.42% chose this answer: “Confirm her current AID system and review pregnancy specific glucose targets, capabilities, settings and limitations before recommending any changes.”
Great job! You chose the best answer. The first step is to confirm the specific AID system and review its pregnancy-specific indications, glucose targets (as stated in rationale answer C), algorithm capabilities, and current settings. CJ’s postprandial readings of 170β220 mg/dL are above pregnancy-specific glucose targets, but the appropriate intervention depends on the system and the pattern identified on the updated AGP report. Further assessment may include meal and bolus timing, carbohydrate entries, insulin-to-carbohydrate ratios, correction settings, and other system-specific parameters. Any insulin adjustments should be made in collaboration with her diabetes and pregnancy care team.
We hope you appreciate this weekβs rationale! Thank you so much for taking the time to answer our Test You Knowledge Tuesday and participate in this fun learning activity!
πUpdated Schedule: ADA Boot Camp, Tech, MNT & More
Live in Beautiful San Diego – Oct 22-23, 2026
Re-Ignite your Passion & Prepare for Diabetes Certification Exams
π Earn 30+ CEs: AMA PRA Category 1 Creditsβ’, ACPE, ANCC, and CDR!
π
2-Day Conference
Oct 22β23, 2026
β±οΈ
15.5 Live CEs
+ 17 bonus CEs
π
CDCES & BC-ADM
Exam Prep + Renewal
π
San Diego, CA
1.7 mi from airport
The field of diabetes care is expanding and evolving rapidly. This unique training conference will keep you on the cutting edge plus prepare you for certification exams. It also fulfills the Standards of Care renewal requirement. Join us for two days of intensive education that is fun and inspiring. Add on the optional Day 3 (Engaging the Disengaged), to complete your conference exeperience.
Coach Beverly and Diana Isaacs, PharmD, BC-ADM, CDCES co-lead an exciting day that brings the ADA and AACE Standards to life. Gain fresh insights, practical tools, and a deeper understanding of the latest in person-centered diabetes care. After attending, you will be empowered to share the latest in diabetes care with your colleagues and the people in your care.
Take your knowledge to the next level with this intensive deep-dive into insulin therapy, dosing and pattern management with Dr. Diana Isaacs. Next, stay for the diabetes tech show-and-tell as Diana demonstrates the specs of the latest pumps and sensors. After lunch, nutrition whiz Christine Craig, MS, RDN, CDCES expertly details the latest in MNT and provides real strategies on translating this content to your clinical practice. You will have a chance to put it all together as Coach Beverly leads you through a series of case studies that integrates content from Day 1 and Day 2.
On Saturday, join this exceptional day-long program led by William H. Polonsky, PhD, CDCES & Susan Guzman, PhD (Behavioral Diabetes Institute) that reveals psychosocial forces behind diabetes self-management β tools to break through resistance and inspire change.
Read more below
π Essentials
Registration
+ Printed Syllabus
$559.00
π Deluxe
Essentials
+ ADA Standards Book
$589.00
π Complete – Best Value!
Deluxe
+ ADCES Review Guide e-Book
$669.00

Transform how you engage patients with diabetes β master behavior change, reduce distress, and overcome medication hesitancy.
Why do so many patients know what they should do β but still struggle to do it?
The answer lies in the psychology of diabetes.
In this transformative full-day course, world-renowned experts William H. Polonsky, PhD, CDCES, and Susan Guzman, PhD, from the Behavioral Diabetes Institute reveal the hidden psychosocial forces that drive β or derail β diabetes self-management.
Youβll walk away with a completely new toolkit for breaking through patient resistance, dissolving medication hesitancy, and creating clinical encounters that actually inspire change!